The World Health Organization says it is resuming
hydrochloroquine trial for treatment of COVID-19 patients.
On May 22, a study published by The Lancet, a medical
journal, claimed that chloroquine had no positive effect on the treatment of
COVID-19 among 96,032 sampled patients.
Three days later, Tedros Ghebreyesus, the WHO
director-general, announced a “temporary pause” in the WHO solidarity trial of
the drug, while citing the study.
Addressing a virtual press conference on Wednesday, Tedros
said the drug trial will now commence in the quest of finding a solution to the
virus.
He said findings by the WHO data safety monitoring board
revealed that there was no reason to discontinue the trial after reviewing
available data on the drug.
Tedros said the executive group endorsed the recommendation,
adding that “all arms of the solidarity trial” will continue.
“Last week, the executive group of the Solidarity Trial
decided to implement a temporary pause of the hydroxychloroquine arm of the
trial, because of concerns raised about the safety of the drug,” he said.
“This decision was taken as a precaution while the safety
data were reviewed. The data safety and monitoring committee of the solidarity
trial has been reviewing the data.
“On the basis of the available mortality data, the members
of the committee recommended that there are no reasons to modify the trial
protocol.
“The executive group received this recommendation and
endorsed continuation of all arms of the solidarity trial, including
hydroxychloroquine. The executive group will communicate with the principal
investigators in the trial about resuming the hydroxychloroquine arm of the
trial.
“The data safety and monitoring committee will continue to
closely monitor the safety of all therapeutics being tested in the solidarity
trial.”
This development is coming few hours after an investigation revealed that the suspension of hydroxychloroquine trial by WHO was based on questionable data.Based on available data, the #COVID19 Solidarity Trial Data Safety & Monitoring Committee recommended there are no reasons to modify the trial protocol. The Executive Group endorsed the continuation of all arms of the Trial, including the use of hydroxychloroquine. https://t.co/r88DVEvZ3j pic.twitter.com/cYITShxcE7— Tedros Adhanom Ghebreyesus (@DrTedros) June 3, 2020
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com